Platinum-Based Drug

Phase 3Small molecule

Platinum-Based Drug is one of 111 small molecule programs targeting Esophageal Squamous Cell Carcinoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

110

Competitors

Pipeline

Status by Indication[3][1]

Indication

Esophageal Squamous Cell CarcinomaActive, not recruiting

Esophageal CancerActive, not recruiting

Ovarian CancerActive, not recruiting

Esophageal Squamous Cell CarcinomaPhase 2

Active, not recruiting

Esophageal CancerPhase 3

Active, not recruiting

Ovarian CancerPhase 2/Phase 3

Active, not recruiting

Competition

Competitive Landscape

836 competitors in Ovarian Cancer

#DrugCompanyPhaseTrials

Cytoxan

BBaxter Healthcare Corporation

Phase 3

21 2

Trodelvy

Gilead

Phase 3

3 3

Tylenol

KKenvue Brands

Phase 3

1 4

H2 Receptor Antagonist

Merck & Co.

Phase 3

1 5

H1 Receptor Antagonist

Merck & Co.

Phase 3

1 6

Masitinib

AAB Science

Phase 3

1 7

Azenosertib

KK-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.

Phase 3

2 8

TLK286

TTelik

Phase 3

5 9

Platinum-Based Drug

ZZhejiang Cancer Hospital

Phase 3

1 10

Phenoxodiol

MMEI Pharma, Inc.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Esophageal Cancer2 trials

Radiotherapy With or Without Concurrent Chemotherapy for Extensive Lymphatic Metastasis of Esophageal Cancer - 3JECROG P-03

Unknown status·CChinese Academy of Medical Sciences·Phase 3·NCT03328234·2 enrolled

Radiotherapy With or Without Concurrent Chemotherapy for Limited Lymphatic Metastasis of Esophageal Cancer - 3JECROG P-02

Unknown status·CChinese Academy of Medical Sciences·Phase 3·NCT03308552·164 enrolled

Esophageal Squamous Cell Carcinoma1 trial

A Study of Toripalimab Combined With Concurrent Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma.

Suspended·ZZhejiang Cancer Hospital·Phase 2·NCT04084158·100 enrolled

Immunochemotherapy1 trial

Radiotherapy Combined With ICIs as Treatment for LA-NSCLC After Failing Induction Immunochemotherapy

Unknown status·ZZhejiang Cancer Hospital·Phase 3·NCT06031597·105 enrolled

Non-squamous NSCLC1 trial

Durvalumab and Tremelimumab ± Platinum-Based Chemotherapy in Patients With Metastatic Squamous or Non-Squamous NSCLC

Active, not recruiting·CCanadian Cancer Trials Group·Phase 2·NCT03057106·301 enrolled

Ovarian Cancer1 trial

Efficacy of Platinum-based Chemotherapy in Platinum-resistant Ovarian Cancer) (EPITOC)

Unknown status·—·Phase 2/3·NCT04055038·164 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for Platinum-Based Drug. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Platinum-Based Drug compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Platinum-Based Drug. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Zhejiang Cancer Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: ZZhejiang Cancer Hospital

Platinum-Based Drug

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Esophageal Cancer2 trials

Esophageal Squamous Cell Carcinoma1 trial

Immunochemotherapy1 trial

Non-squamous NSCLC1 trial

Ovarian Cancer1 trial

References

Drug Info

Quick Facts

Related News